All News

Investigators are currently assessing QTX-2101 among patients with acute promyelocytic leukemia in a phase 3 trial.

Phase 2 PFLT-PC data revealed no significant disease was seen in 84% of patients treated with cooled laser focal therapy for prostate cancer at 3 months.

In the PATINA trial, adding palbociclib to maintenance therapy significantly improved progression-free survival in patients with HR+, HER2+ breast cancer.

The FDA has assigned a Prescription Drug User Fee Act date of November 14, 2026, for the ivonescimab-based combination.

The developer now plans to initiate a first-in-human clinical trial among patients with recurrent high-grade glioma.

Approval of the larger vial size may offer more dosing flexibility for pediatric and adult patients with T-cell ALL or LBL.

A new guideline from ASCO and Ontario Health conditionally recommends the use of daratumumab for patients with high-risk smoldering multiple myeloma.

PSMA-PET could be considered in selective cases, given its modest sensitivity and prognostic value in intermediate-risk prostate cancers.

Any-grade treatment-emergent immune-mediated AEs occurred in 22% of patients with early-stage lymphoma treated with the ADC-based regimen.

People who consumed 14 or more drinks per week experienced a higher risk of colorectal cancer compared with those who consumed one or fewer drinks.

Findings from the phase 1b/2 TENACITY-01 trial, which is assessing CTD402 monotherapy in these hematologic malignancies, supported the agency’s decision.

Adding ANPEP and PIGR to a biomarker blood panel of CA19-9 and THBS2 significantly improved the detection rate of any-stage pancreatic cancer.

Results of 9 patients with metastatic breast cancer dosed with Bria-IMT have shown sustained survival.

The FDA held a Type B meeting regarding the use of d3-T, a form of testosterone, and the risk of developing breast cancer in women.

Researchers have generated a high-resolution spatial atlas of the human gastrointestinal tract in aGVHD, revealing epithelial disruption and unexpected immune cell patterns that reshape how the disease is understood.

Findings from the phase 1/2 BRUIN trial support the Notice of Compliance with conditions for pirtobrutinib in this relapsed/refractory disease population.

Data from the phase 3 CEPHEUS trial support the approval of the daratumumab-based regimen among patients with newly diagnosed multiple myeloma.

Following 2 prior CRLs from the FDA for the rivoceranib plus camrelizumab regimen in frontline HCC, the developer has again submitted an NDA to the FDA.

Data from the phase 3 PEAK trial demonstrate that bezuclastinib plus sunitinib may be favorable vs sunitinib alone in certain patients with GISTs.

Paxalisib combined with pembrolizumab and chemotherapy showed preliminary activity in patients with metastatic triple-negative breast cancer.

Anbenitamab plus chemotherapy reduced the risk of progression or death by 75% vs chemotherapy alone in select patients with gastric cancer/gastroesophageal adenocarcinoma.

Investigators are currently assessing IBI3003 among patients with relapsed/refractory multiple myeloma in a phase 1/2 trial.

Researchers have found that engineering CAR T cells to target Tenascin-C, an extracellular matrix protein enriched in glioblastoma, can shrink tumors and prolong survival in preclinical brain tumor models while sparing healthy tissue.

Experts discuss new modalities such as HPV vaccines, balancing hope with realism, and other considerations in cervical cancer management.

A correlation between miR-93-5p and basal-like tumor features was observed among urinary samples of patients with bladder cancer.

Data from the ENDURE trial may contextualize prior evidence suggesting an interferon-related improvement in treatment-free remission rates in CML.

A phase 3 trial of iSCIB1+, a novel cancer vaccine, assessing patients with advanced melanoma has been cleared by the FDA.

Patients with cervical cancer with cachexia, sarcopenia, and malnutrition had higher mortality when receiving concurrent chemoradiotherapy.

The BC-RADS-2 study aimed to address diagnostic delays and cancer care disparities of patients with breast cancer in low- and middle-income countries.

Nathan Goodyear, MD, discussed key insights in integrative oncology care as well as evidence-based patient-centric tools that may optimize QOL outcomes.